Our co-development model is designed for forward-thinking companies that seek a trusted, strategic partner to co-create and bring innovative pharmaceutical products to market. This collaborative approach combines the strengths of both parties, driving efficiency, reducing risks, and accelerating time-to-market
Collaborative Approach
Co-development allows for shared risks and rewards between Aizant and our partner. Both parties contribute their specialized knowledge, whether it’s in formulation development, clinical trials, or regulatory approvals, to co-develop a product efficiently and effectively.
Innovative Therapies
We provide co-development opportunities for complex generics, new chemical entities (NCEs), and other high-value specialty products, which require specialized knowledge and technologies. This concept is especially valuable for companies seeking to enter competitive markets with innovative therapies.
Shared Investment and Risk
The co-development concept is built on a collaborative investment in the product development and clinical trials. Both parties share in the costs, risks, and rewards, which helps reducing the financial burden on a single partner while maximizing each other’s abilities.
Regulatory and Commercialization Support
Aizant contributes to the co-development process by handling key aspects such as clinical trial material manufacturing, regulatory filings, clinical trials management, and commercial scale-up, securing the product’s compliance with both market and regulatory requirements.
